Apple unveils future Macs iPhone lookalike big plan - everything you should expect: Apple announced its plan to start manufacturing its own processors for its Mac family, instead of using Intel's, last June. Now, the company is holding another event where it will likely unveil more details about the change, including the announcement of the first laptop that will work with that processor made by Apple.

The move is intended to mark the biggest transformation of Apple's family of Mac computers in recent years, thus signifying a leap that will provide the tech giant even more control over its laptops and desktops. It will also make the Mac experience more consistent with that of the iPhone and iPad, as all Apple apps will run on the same architecture.

That means iPhone apps will be compatible with Mac.

The chips, called Apple Silicon, are based on the A14 Bionic processors that hide at the heart of the iPhone 12 and are expected to translate into better energy efficiency as well as improvements in machine learning for Apple laptops.

The Apple event —its third product launch in the last 3 months-will take place at 10.00 am in Cupertino (California, United States), at 19.00 pm in Spain.

Apple has not revealed any details about what it will announce, but the company already anticipated that its plan was to announce its first computers powered by Apple Silicon before the end of the year. Bloomberg reports also point to Apple's November event focusing on new Apple Silicon devices.

Apple unveils future Macs iPhone lookalike big plan

That announcement would come at a critical time for Apple's Mac family, which has been one of the company's strongest business segments in recent quarters, as people have been working from home due to the pandemic. Apple reported record Revenue for the Mac line of business in the latest economic results presented by the company last month.

Apple is reportedly working on 3 new laptops that will work with Apple Silicon, according to journalists Mark Gurman and Debby Wu of Bloomberg.

The new family will consist of a 13-inch MacBook Pro, a 13-inch MacBook Air and a 16-inch MacBook Pro.

The two smaller laptops are likely to be announced during the November 10 event, as they are more advanced in terms of their production phase, as published by Bloomberg.

The company, it seems, would also be working on a new redesigned iMac and a revamped Mac Pro, but details on either device are unlikely to be seen during Tuesday's event.

The head of Apple's Hardware division, Johny Srouji, said in June that Apple Silicon would bring significant performance improvements to Mac computers.

But the company was not very specific about those performance improvements and new features at WWDC 2020, its annual meeting for developers, where this new chip was talked about for the first time. Instead, it demonstrated how processors could handle demanding tasks in applications like Adobe Photoshop and Final Cut Pro.

If Apple unveils the first laptops that will work with Apple Silicon, it will probably also provide more details about the improvements that the chip will mean and the novelties that users can expect.

It can also provide some details on how app makers have been embracing the transition since Apple began providing development kits in June to kick off the same. Apple also discussed how it planned to support current Mac applications during WWDC.

Macs with Apple Silicon aren't the only products we expect to see from Apple in the near future.

The company is also rumored to be working on its first pair of high-quality circumaural (over-Ear, those that completely surround the ear) headphones, which could be released as AirPods Studio, as well as a location tracking accessory called AirTags, as published by Bloomberg, 9to5Mac, MacRumors, and other media.

There is a possibility that Apple will use its November 10 event as an opportunity to unveil some of these products. But the event is expected to focus primarily on the new Mac family.

The launch of its own computer chip is a milestone for the Mac. Apple laptops and desktops are its only major products that did not previously work with chips made by the company itself: the iPhone, iPad, Apple Watch and Apple TV work with Apple processors.

This will give Apple much more flexibility in terms of release times, as it will not have to update or release new Mac laptops according to Intel's release schedule.

It also means that Apple will have more freedom to develop Mac-specific features that more closely integrate the device's hardware and software, an approach that has been adopted with the iPhone, Apple Watch and other products.

The switch to Apple Silicon could ultimately define Apple's direction for its line of laptops and desktops, and Apple CEO Tim Cook already hinted at this during WWDC.

"When we look forward, we imagine some amazing new products," Cook said during the presentation. "And the transition to our own custom chip is what will allow us to bring them to life."

Apple will probably offer a more detailed view of its future strategy next November 10.

Apple unveils future Macs iPhone lookalike big plan

More news:

A flu vaccine produced with the tobacco plant instead of chicken eggs shows promising results and could represent a real medical revolution

Seasonal influenza remains today a considerable threat to public health despite the availability of specific vaccines against it.

In our country alone around half a million people pass this infection every year, causing 35,300 hospitalizations and 6,300 deaths, according to the Influenza Surveillance System in Spain.

Hence, research remains focused on moving towards increasingly successful methods against the virus.

In this scenario, a new influenza vaccine grown from plants has shown optimistic results on a large scale, which could mean a health revolution.

To date, influenza vaccines are obtained every year from virus particles extracted from chicken eggs or cells grown in the laboratory. For this new vaccine however, the viral particles were obtained from a relative of the tobacco plant native to Australia, genetically altered to produce the viral proteins.

Tested in 2 combined trials involving nearly 23,000 participants, the results point to not only that it is safe, but that its success is comparable even to that of vaccines currently marketed.

Researchers from the McGill University Health Centre Research Institute, Montreal, (Canada) developed a flu vaccine based on the Nicotiana benthamiana plant, an Australian relative of the tobacco plant. This species was designed to generate particles similar to the outer layer of the influenza virus.

Then the plant-based vaccine was subsequently tested in 2 combined trials, in Phase III, funded by the Canadian biotechnology company that developed the technique, according to Sciencie Alert.

The first of the studies aimed to show the effectiveness of the treatment, so the researchers wanted to show that it could prevent 70% of the participants from developing flu-like respiratory diseases during the season. The test involved more than 10,000 participants from Asia, Europe and North America, aged between 18 and 64.

Although the results did not reach this proportion, the vaccine has managed to be effective in one-third of patients for influenza strains circulating in the winter of the northern hemisphere 2017-2018. Something more similar than you think with the effectiveness of vaccines that are marketed each year.

The second study recruited 12,700 patients over the age of 65 who did not live in residences or medical centers or had previous health problems.

"Like other flu vaccines, antibody responses to the [plant-derived] vaccine also decreased with age," note the authors of the research published in The Lancet. Despite this, a significant increase in immune cells designed to respond to influenza-like infections was found.

"These efficacy studies are the first large-scale studies of any human plant-derived vaccine. Together, they show that the plant-derived vaccine can provide substantial protection against respiratory diseases and influenza-like diseases caused by influenza viruses in adults. The vaccine was well tolerated and no important safety signs emerged in the participants in the two studies, " the conclusions read.

Although more research is needed, the results open a hopeful path in the battle to contain this disease every year. The possibility of generating these preventive treatments from plants grown on a large scale could have an impact on increased global production capacity for seasonal influenza vaccines.

You may also find interesting: